Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Metformin/Gliclazide Bioavailability
NCT03467971Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gliclazide + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration and 1 more. Started Mar 2018; status: completed.
02
Drugs
gliclazide + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03467971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467971.